Key result
Among East Asian patients with acute VTE, edoxaban resulted in a symptomatic recurrent VTE rate of 2.8% compared to 4.5% with warfarin (HR 0.64; 95% CI 0.34-1.19; P=0.1601).
Why the study?
Does edoxaban reduce symptomatic recurrent VTE and clinically relevant bleeding compared to warfarin in East Asian patients with acute VTE?
RCT (n=1,109)
double-blind
randomized
Yes
Does edoxaban reduce symptomatic recurrent VTE and clinically relevant bleeding compared to warfarin in East Asian patients with acute VTE?
Hazard Ratio: 0.64 (95% CI 0.34–1.19)
Absolute Event Rate: 2.8% vs 4.5%
p-value: p=0.1601
Edoxaban is an effective and safer alternative to warfarin for the treatment of acute VTE in East Asian patients, significantly reducing clinically relevant bleeding.
No takes yet. Share an insight, caveat, or question.
Edoxaban was not superior to warfarin for recurrent VTE prevention in East Asians; extends global RCT data to this population.
Nakamura et al. (2015) conducted an RCT in venous thromboembolism (VTE) (n=1,109). edoxaban vs. heparin overlapped with and followed by warfarin was evaluated on symptomatic recurrent VTE (HR 0.64, 95% CI 0.34-1.19, p=0.1601). Among East Asian patients with acute VTE, edoxaban resulted in a symptomatic recurrent VTE rate of 2.8% compared to 4.5% with warfarin (HR 0.64; 95% CI 0.34-1.19; P=0.1601).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: